Established in 2017, Pin Therapeutics is a biotechnology company specializing in the field of Targeted Protein Degradation (TPD). With operations in South Korea and the San Francisco Bay Area, the company focuses on developing small molecule-based therapeutics aimed at treating various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. Pin Therapeutics employs a chemical biology-driven approach to protein degradation, utilizing bifunctional compounds that harness the ubiquitin-proteasome system to selectively degrade target proteins within cells.

PROTAC Technology: Pin Therapeutics leverages Proteolysis Targeting Chimeras (PROTACs), which are bifunctional molecules designed to recruit E3 ubiquitin ligases to target proteins, leading to their ubiquitination and subsequent degradation by the proteasome. This approach allows for the selective elimination of disease-causing proteins that are otherwise difficult to target with traditional small molecules.

Private

Biotech